Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Stock Information for Avalon GloboCare Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalon GloboCare Corp.

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
Avalon Globocare to Present at the LD Micro Main Event XV on October 26th
Avalon GloboCare Receives Allowance for Joint U.S. Patent
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.